Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide

Bibliographic Details
Title: Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
Authors: Sarah M Michienzi, Mikayla Johnson, Thomas D Chiampas, Eric Wenzler, Rodrigo M Burgos, Renata O Smith, Melissa E Badowski
Source: Drugs in Context, Vol 10, Pp 1-6 (2021)
Publisher Information: BioExcel Publishing Ltd, 2021.
Publication Year: 2021
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: antiretroviral, hiv, reverse transcriptase inhibitor, switch, tenofovir, Therapeutics. Pharmacology, RM1-950
More Details: Although tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have been evaluated in various clinical trials, limited safety and efficacy data exist in real-world settings. The goal of this retrospective analysis is to assess changes in virological suppression, immunological status, renal function, weight and body mass index (BMI) amongst people living with HIV who switched from a TDF-based to a TAF-based regimen. Of 130 patients included in the final analysis, 53 patients experienced an increase in their viral load upon switching from TDF to TAF therapy whilst 62 patients remained undetectable. For those who experienced a viral blip, 33 (62%) resuppressed by the time of last follow-up, 15 (28%) patients did not have additional labs beyond the last follow-up and concern for failure occurred in 5 (9%) patients. No differences in immunological function, renal function, weight or BMI were observed from before switching to the last follow-up. Although a loss of virological suppression was found upon switching to TAF at subsequent follow-up visits, resuppression ultimately occurred in most patients.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1740-4398
Relation: https://drugsincontext.com/real-world-impact-of-switching-from-tenofovir-disoproxil-fumarate-to-tenofovir-alafenamide; https://doaj.org/toc/1740-4398
DOI: 10.7573/dic.2021-2-1
Access URL: https://doaj.org/article/59c8178f2e7c4937891fdf0c3583f0cc
Accession Number: edsdoj.59c8178f2e7c4937891fdf0c3583f0cc
Database: Directory of Open Access Journals
More Details
ISSN:17404398
DOI:10.7573/dic.2021-2-1
Published in:Drugs in Context
Language:English